Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.
about
Endoluminal stents for superficial femoral and popliteal artery occlusions in patients with lower limb peripheral artery diseasePeriprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventionsNew developments in the clinical use of drug-coated balloon catheters in peripheral arterial diseaseKorean Guidelines for Interventional Recanalization of Lower Extremity ArteriesAcute reductions in mechanical wall strain precede the formation of intimal hyperplasia in a murine model of arterial occlusive disease.Minimally invasive revascularization strategies for chronic lower limb ischemia.[PTA and stent placement distal to the superficial femoral artery]Current state of endovascular treatment of femoro-popliteal artery disease.Peripheral atherectomy: a critical review.Rupture and migration of an endovascular stent in the brachiocephalic trunk causing a vertebral steal syndrome.Antiplatelet and anticoagulant drugs in interventional radiology.Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stentTargeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields.Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammationStenting for peripheral artery disease of the lower extremities: an evidence-based analysis.Endovascular treatment of femoral-popliteal diseaseThe primary patency and fracture rates of self-expandable nitinol stents placed in the popliteal arteries, especially in the P2 and P3 segments, in Korean patientsBalloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions.First human trial of KW39 slotted-tube stents: for percutaneous coronary interventionEndovascular intervention for peripheral artery disease.Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery diseaseComparison of diamond-like carbon-coated nitinol stents with or without polyethylene glycol grafting and uncoated nitinol stents in a canine iliac artery model.Superficial femoral artery: current treatment options.The engineering of endovascular stent technology: a review.Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized TrialDrug-eluting stents in the management of peripheral arterial diseaseCurrent endovascular therapy for lower extremity peripheral arterial disease: indications, outcomes and modalities.Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model.Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation.Intravascular foreign bodies: danger of unretrieved fragmented medical devices.Local drug delivery for treatment of coronary and peripheral artery disease.Stent fracture in the coronary and peripheral arteries.Peripheral artery disease. Part 2: medical and endovascular treatment.Current state of diagnosis and management of critical limb ischemia.Drug-coated balloons for coronary and peripheral interventional procedures.Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis.The current role of endovascular intervention in the management of diabetic peripheral arterial diseaseEndovascular treatment of critical ischemia in the diabetic foot: new thresholds, new anatomies.Drug-coated balloons and their place in treating peripheral arterial disease.Endovascular stents: a review of their use in peripheral arterial disease.
P2860
Q24244722-4ED71F15-CE31-47FA-8B31-29F7002F1AC5Q26740181-0F123CA9-AE43-4230-8F9C-10230E066113Q26740218-76344E23-063C-4054-AC32-DE1C37D81DB1Q26801709-63A02C9E-A7E1-4730-8A5E-E59C939C6784Q30399953-E1C0C2BC-5AE9-4F82-A886-64FA60D80DADQ33236821-B0947E38-E606-42D7-899B-78F0A87F21E7Q33260168-5882F595-FE6F-4B04-B637-6CC625BE19B1Q33298566-27D0750E-5842-44B2-8B87-46880D2EFEA9Q33307441-A97E4F57-6AFF-47A3-B874-C026C1D21CBEQ33313098-F7BB1C9A-589B-4E21-83E4-4993CCC6AF8CQ33395898-87FD5D3E-EE97-4996-A79A-9FC5D7C52C74Q33710114-680AC7C8-980A-4F39-A078-BA676B2CED29Q33929284-99EBA9DF-24AB-4902-9CAB-A0E61AF89FEFQ34018425-926D6AA3-0892-4444-8D59-4135345F6C95Q34449178-5D8CCC6D-3F31-44BD-AD03-892F0FC3F355Q34563744-25AB3BC3-104A-41AD-A5E2-D05B6EB0AA4AQ34642030-D8F6D521-6613-4B46-8DCD-D78BE05CB929Q35009691-284F6A4E-9FC0-41F2-BA7B-E2C5BBD6C61EQ35594750-AE1C127D-2475-463E-8D1E-83712C821ABBQ35857220-85BF64B4-0AC3-4526-9091-5ED8CB80C847Q35866198-B4412460-2292-4C1C-887A-04EA6E2F72E6Q36325343-B127C6DF-301B-4986-B2EC-00EABB6DEE0CQ36401455-12EEEA7C-5AFC-49FC-9D72-0158C5D2FFDFQ36441888-17E53B0D-B736-4F48-A20A-7A0559E481F7Q36774583-9C1B462F-7298-4D99-AD29-541A70C64EBDQ36835836-05C9E72D-D9B4-4380-8FED-8F4AF5F2FD67Q36982443-ABAE1F5D-616F-4A85-86EC-7494FC20CA69Q37456910-90C42CA7-5886-4EDF-9A12-132D0DB24F9DQ37463102-B0AF7A4E-6899-4D59-8B04-B3FB1F90054CQ37523440-63B76132-85EE-480F-9DCD-1F0BBE00B4F3Q37765610-E1DD6BAC-71CF-488A-8FA4-155700533662Q37784167-C85ABEF0-AD2C-4A67-81B6-9AE5798A9990Q37889106-B312C5B0-9E89-416E-BE89-7EE87E916A21Q37981977-0E98DE8D-1087-419D-9135-865EA772D090Q38028877-B009CB40-6CE3-48A6-82D4-492DE7BE6F6CQ38034502-2760A542-A794-42F6-9CBA-FD9F17377DD2Q38050775-A336FCCD-7519-401E-ADAC-2841017FB455Q38058074-2D40382D-0E89-497C-9F3A-CF3470A6C9EDQ38070705-4A7B6FAC-D394-44C1-A04E-6112D3F05D95Q38098451-F72CB3B9-60D3-4244-8B21-429093508F5E
P2860
Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@en
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@nl
type
label
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@en
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@nl
prefLabel
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@en
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@nl
P2093
P1476
Sirolimus-eluting versus bare ...... disease: the SIROCCO II trial.
@en
P2093
Alexander Tielbeek
Alexandra Lansky
Benjamin Wiesinger
Catharina Mudde
Dierk Scheinert
Gunnar Tepe
Hans Tielemans
Jean P Bérégi
Johannes Lammer
John Anderson
P304
P356
10.1097/01.RVI.0000151260.74519.CA
P577
2005-03-01T00:00:00Z